Shriya K. Garg BS, Khushi Kohli BA, Isha K. Garg BS, Yash K. Garg BS, Lilac G. Nguyen BS, Isabella S. Nguyen BS, Erin Jay G. Feliciano MD, MBA, Yefri A. Baez MD, Brandon A. Mahal MD, Puneeth Iyengar MD, PhD, Daniel R. Gomez MD, MBA, Kaitlyn Lapen MD, Edward Christopher Dee MD
{"title":"美国西班牙裔乳腺癌、肺癌和前列腺癌患者接受姑息性治疗的差异","authors":"Shriya K. Garg BS, Khushi Kohli BA, Isha K. Garg BS, Yash K. Garg BS, Lilac G. Nguyen BS, Isabella S. Nguyen BS, Erin Jay G. Feliciano MD, MBA, Yefri A. Baez MD, Brandon A. Mahal MD, Puneeth Iyengar MD, PhD, Daniel R. Gomez MD, MBA, Kaitlyn Lapen MD, Edward Christopher Dee MD","doi":"10.1002/cncr.35903","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Despite palliative-intent interventions’ ability to improve the quality of life of patients, significant inequalities persist in uptake. Such disparities are characterized by racial, socioeconomic, and geographic factors. However, less is known among disaggregated Hispanic populations. This study examines disparities in the receipt of palliative-intent interventions among Hispanic subgroups with advanced lung, breast, and prostate cancer.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Via the National Cancer Data Base, data were collected on the receipt of palliative-intent interventions among Hispanic subgroups diagnosed with American Joint Committee on Cancer analytic stage IV breast, lung, and prostate cancer between 2004 and 2021. Multivariate logistic regressions were conducted to quantify differences in the uptake of palliative-intent care among Hispanic subgroups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 945,894 total patients, disaggregated analyses revealed reduced receipt of palliative-intent interventions for patients with lung, breast, and prostate cancer of Mexican descent (lung, <i>p</i> < .001; breast, <i>p</i> < .001; prostate, <i>p</i> = .03) compared to non-Hispanic White patients. Receipt for patients of South or Central American descent was reduced in comparison to non-Hispanic White patients for lung and breast cancer (lung, <i>p</i> < .001; breast, <i>p</i> < .001). Uptake of palliative interventions for metastatic lung and breast cancer was reduced for patients of Cuban descent (lung, <i>p</i> < .001; breast, <i>p</i> = .03), and was lower for patients of Dominican descent with breast cancer, compared to non-Hispanic White patients (<i>p</i> = .05).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>These findings demonstrate disparities in the receipt of palliative-intent interventions among disaggregated Hispanic subgroups. This study highlights the need for disaggregated research to further characterize these disparities and their drivers. Community-level and patient-centric efforts may help to address these inequities.</p>\n </section>\n </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 10","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States\",\"authors\":\"Shriya K. Garg BS, Khushi Kohli BA, Isha K. Garg BS, Yash K. Garg BS, Lilac G. Nguyen BS, Isabella S. Nguyen BS, Erin Jay G. Feliciano MD, MBA, Yefri A. Baez MD, Brandon A. Mahal MD, Puneeth Iyengar MD, PhD, Daniel R. Gomez MD, MBA, Kaitlyn Lapen MD, Edward Christopher Dee MD\",\"doi\":\"10.1002/cncr.35903\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Despite palliative-intent interventions’ ability to improve the quality of life of patients, significant inequalities persist in uptake. Such disparities are characterized by racial, socioeconomic, and geographic factors. However, less is known among disaggregated Hispanic populations. This study examines disparities in the receipt of palliative-intent interventions among Hispanic subgroups with advanced lung, breast, and prostate cancer.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Via the National Cancer Data Base, data were collected on the receipt of palliative-intent interventions among Hispanic subgroups diagnosed with American Joint Committee on Cancer analytic stage IV breast, lung, and prostate cancer between 2004 and 2021. Multivariate logistic regressions were conducted to quantify differences in the uptake of palliative-intent care among Hispanic subgroups.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Among 945,894 total patients, disaggregated analyses revealed reduced receipt of palliative-intent interventions for patients with lung, breast, and prostate cancer of Mexican descent (lung, <i>p</i> < .001; breast, <i>p</i> < .001; prostate, <i>p</i> = .03) compared to non-Hispanic White patients. Receipt for patients of South or Central American descent was reduced in comparison to non-Hispanic White patients for lung and breast cancer (lung, <i>p</i> < .001; breast, <i>p</i> < .001). Uptake of palliative interventions for metastatic lung and breast cancer was reduced for patients of Cuban descent (lung, <i>p</i> < .001; breast, <i>p</i> = .03), and was lower for patients of Dominican descent with breast cancer, compared to non-Hispanic White patients (<i>p</i> = .05).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>These findings demonstrate disparities in the receipt of palliative-intent interventions among disaggregated Hispanic subgroups. This study highlights the need for disaggregated research to further characterize these disparities and their drivers. Community-level and patient-centric efforts may help to address these inequities.</p>\\n </section>\\n </div>\",\"PeriodicalId\":138,\"journal\":{\"name\":\"Cancer\",\"volume\":\"131 10\",\"pages\":\"\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-05-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35903\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35903","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景尽管姑息意图干预能够改善患者的生活质量，但在接受方面仍然存在显著的不平等。这种差异的特点是种族、社会经济和地理因素。然而，在分类的西班牙裔人群中，人们知之甚少。本研究考察了西班牙裔晚期肺癌、乳腺癌和前列腺癌亚组患者接受姑息性干预的差异。方法通过国家癌症数据库，收集2004年至2021年间美国癌症联合委员会诊断为IV期乳腺癌、肺癌和前列腺癌的西班牙裔亚组接受姑息性干预的数据。进行多变量logistic回归以量化西班牙裔亚组间姑息治疗意向吸收的差异。结果：在945,894名患者中，分类分析显示，墨西哥裔肺癌、乳腺癌和前列腺癌患者接受姑息性干预的次数减少(lung, p <；措施;乳房，p <；措施;前列腺癌，p = .03)与非西班牙裔白人患者相比。与非西班牙裔白人肺癌和乳腺癌患者相比，南美或中美洲血统患者的收纳量减少(lung, p <；措施;乳房，p <；措施)。古巴裔患者对转移性肺癌和乳腺癌姑息性干预的采用减少(肺，p <；措施;与非西班牙裔白人患者相比，多米尼加裔乳腺癌患者的死亡率更低（p = 0.05）。结论：这些发现表明，在西班牙裔亚组中，接受姑息性干预的差异。这项研究强调需要进行分类研究，以进一步表征这些差异及其驱动因素。社区层面和以患者为中心的努力可能有助于解决这些不平等问题。
Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States
Background
Despite palliative-intent interventions’ ability to improve the quality of life of patients, significant inequalities persist in uptake. Such disparities are characterized by racial, socioeconomic, and geographic factors. However, less is known among disaggregated Hispanic populations. This study examines disparities in the receipt of palliative-intent interventions among Hispanic subgroups with advanced lung, breast, and prostate cancer.
Methods
Via the National Cancer Data Base, data were collected on the receipt of palliative-intent interventions among Hispanic subgroups diagnosed with American Joint Committee on Cancer analytic stage IV breast, lung, and prostate cancer between 2004 and 2021. Multivariate logistic regressions were conducted to quantify differences in the uptake of palliative-intent care among Hispanic subgroups.
Results
Among 945,894 total patients, disaggregated analyses revealed reduced receipt of palliative-intent interventions for patients with lung, breast, and prostate cancer of Mexican descent (lung, p < .001; breast, p < .001; prostate, p = .03) compared to non-Hispanic White patients. Receipt for patients of South or Central American descent was reduced in comparison to non-Hispanic White patients for lung and breast cancer (lung, p < .001; breast, p < .001). Uptake of palliative interventions for metastatic lung and breast cancer was reduced for patients of Cuban descent (lung, p < .001; breast, p = .03), and was lower for patients of Dominican descent with breast cancer, compared to non-Hispanic White patients (p = .05).
Conclusions
These findings demonstrate disparities in the receipt of palliative-intent interventions among disaggregated Hispanic subgroups. This study highlights the need for disaggregated research to further characterize these disparities and their drivers. Community-level and patient-centric efforts may help to address these inequities.
期刊介绍：
The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society.
CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
